Amneal Pharmaceuticals(AMRX)
搜索文档
Amneal Pharmaceuticals(AMRX) - 2019 Q4 - Earnings Call Transcript
2020-02-27 03:08
Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) Q4 2019 Earnings Conference Call February 26, 2020 8:30 AM ET Company Participants Steve Manzano - General Counsel and Corporate Secretary Chirag Patel - Co Chief Executive Officer and President Chintu Patel - Co Chief Executive Officer Todd Branning - Senior Vice President and Chief Financial Officer Joe Todisco - Senior Vice President of Specialty Commercial Conference Call Participants Elliot Wilbur - Raymond James David Amsellem - Piper Jaffray Greg Gilbert - Su ...
Amneal Pharmaceuticals(AMRX) - 2019 Q3 - Quarterly Report
2019-11-07 09:09
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0546926 (State or other jurisdict ...
Amneal Pharmaceuticals(AMRX) - 2019 Q3 - Earnings Call Transcript
2019-11-07 04:53
Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) Q3 2019 Results Conference Call November 6, 2019 8:30 AM ET Company Participants Mark Donohue - Vice President of Investor Relations Chirag Patel - Co-Chief Executive Officer and President Chintu Patel - Co-Chief Executive Officer Todd Branning - Chief Financial Officer Andy Boyer - Executive Vice President of Commercial Operations Joe Todisco - Senior Vice President of Specialty Commercial Pradeep Bhadauria - Chief Scientific Officer David Buchen - Chief Legal O ...
Amneal Pharmaceuticals(AMRX) - 2019 Q2 - Quarterly Report
2019-08-06 04:39
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-054692 ...
Amneal Pharmaceuticals(AMRX) - 2019 Q1 - Quarterly Report
2019-05-10 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-05469 ...
Amneal Pharmaceuticals(AMRX) - 2018 Q4 - Annual Report
2019-03-01 21:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (S ...